Crisaborole vesus tacrolimus ointment in the treatment of atopic dermatitis

A Comparative evaluation of the efficacy and safety of 2% crisaborole versus 0.1% tacrolimus ointment for the topical treatment of mild to moderate atopic dermatitis - nil

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/05/067660

Enrollment

Registered

2024-05-20

Start date

Unknown

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: L209- Atopic dermatitis, unspecified

Interventions

Intervention1: crisaborole ointment: 2% crisaborole ointment topically for mild to moderate atopic dermatitis twice daily Control Intervention1: tacrolimus ointment: 0.1% tacrolimus ointment topically

Eligibility

Inclusion criteria

Inclusion criteria: Patients to be aged 2 years or older of either sex They must have a clinical diagnosis of AD according to Hanifin and Rajka criteria They should have 5% or more treatable body surface area involvement, and a baseline Investigator’s Static Global Assessment (ISGA) score of mild (2) or moderate (3).

Exclusion criteria

Exclusion criteria: active infections or use of topical steroids in last 14 days

Design outcomes

Primary

Measure	Time frame
To determine the efficacy of 2% crisaborole ointment for treating mild to moderate cases of AD to achieve a clear or near clear skin (ISGA score 0 or 1) at baseline and in 4 weeks.Timepoint: At baseline and in 4 weeks	—

Secondary

Measure	Time frame
To determine the change in pruritus score with both the treatment groups and compare between themTimepoint: 4 weeks	—

Countries

India

Contacts

Public ContactDisha Chakraborty

Calcutta National Medical College and Hospital

docdishachaks@gmail.com9674074135

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026